Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01270698 · ClinicalTrials.gov registry record · Phase 1
Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01270698 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 26 participants.
The verdict
NCT01270698, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a Phase I trial to study the safety of IMMU-130. IMMU-130 is composed of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a common chemotherapy drug used for colorectal cancer. Antibodies are proteins normally made by the immune system. They bind to substances that don't belong in the body to prevent harm to the body. The antibody in this study was designed to bind to a marker located on colorectal cancer tumors. The antibody was originally made from mouse proteins, but was changed in the laboratory to be more like human antibodies. This study will investigate how IMMU-130 acts for the treatment of colorectal cancer. The study is mainly being done to see if IMMU-130 is safe.
Interventions
- DRUG IMMU-130
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01270698
The ClinicalTrials.gov registry entry for NCT01270698 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMMU-130 is the first listed.
NCT01270698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01270698 about?
NCT01270698 is a clinical study titled "Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer". This is a Phase I trial to study the safety of IMMU-130. IMMU-130 is composed of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a common chemotherapy drug used for colorectal cancer. Antibodies are proteins normally made by the immune system. They bind to su...
What is the current status of trial NCT01270698?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2011-05. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01270698?
The interventions under investigation include: IMMU-130 (DRUG).
Who is sponsoring clinical trial NCT01270698?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.